Citi Downgrades Allergan (AGN) to Hold
More News related to AGN
- Allergan Announces Quarterly Conference Call
- REMINDER: ORLive Presents: Lap-Band(R) Surgery
- Beacon Equity Issues Trade Alerts on Market Movers: GSPG, POT, PBR, JOYG, AGN, LULU
- Unusual 11 Mid-Day Movers 9/11: BBND, CPSL, CAL, JOYG Higher; LEH, KNXA, IDCC, TKTM Lower
- Allergan (AGN) Reports Positive Results from Two Phase III Trials on BOTOX(R) Headache Treatment
More News related to Downgrades
- UBS Downgrades Southern Copper (PCU) to Neutral
- RBC Capital Downgrades DSP Group (DSPG) to Underperform
- RBC Capital Downgrades Garmin (GRMN) to Underperform
- RBC Capital Downgrades Nortel (NT) to Underperform
- RBC Capital Downgrades Alcatel-Lucent (ALU) to Underperform
Citi downgrades Allergan Inc (NYSE: AGN) from Buy to Hold. Price target lowered from $68 to $54.
Citi analyst says, "AGN's U.S. aesthetics franchise weakness could lead to contagion of ex-US markets in subsequent quarters. The impact appears to be hitting AGN's most expensive breast aesthetics segment followed by dermal fillers and Botox...Strategically, we like the complementary nature of the steady growth therapeutic and high-growth aesthetics lines. Further, management’s ability to use M&As to continually position the company in attractive markets supports our view of AGN as a core long-term holding."
Allergan, Inc. is a multi-specialty healthcare company focused on developing and commercializing pharmaceuticals, biologics and medical devices.
Related Categories
DowngradesStocks Mentioned
-4.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
